00:28 , Feb 2, 2019 |  BC Extra  |  Company News

Deal filing: BMS added CVR late in Celgene negotiations

Celgene Corp. (NASDAQ:CELG) rejected multiple overtures from Bristol-Myers Squibb Co. (NYSE:BMY) and solicited a bid from another pharma before accepting BMS's takeout offer last month -- but not before BMS replaced some guaranteed money with...
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
19:05 , Jan 4, 2019 |  BC Week In Review  |  Company News

New Year splash as BMS to acquire Celgene in $74B deal

The biggest biotech takeout in a decade brings a tumultuous 15 months for Celgene Corp. (NASDAQ:CELG) to an end as Bristol-Myers Squibb Co. (NYSE:BMY) proposed on Jan. 3 to acquire the bellwether for $74 billion....
19:02 , Jan 4, 2019 |  BC Week In Review  |  Company News

BMS deal weighs on Celgene partners

The proposed acquisition of Celgene Corp. (NASDAQ:CELG) by Bristol-Myers Squibb Co. (NYSE:BMY) on Jan. 3 put pressure on shares of Celgene partners Acceleron Pharma Inc. (NASDAQ:XLRN) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) on a day when...
00:57 , Jan 4, 2019 |  BC Extra  |  Company News

BMS deal weighs on Celgene partners

Thursday’s proposed acquisition of Celgene Corp. (NASDAQ:CELG) by Bristol-Myers Squibb Co. (NYSE:BMY) put pressure on shares of Celgene partners Acceleron Pharma Inc. (NASDAQ:XLRN) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) on a day when U.S. stocks across...
14:08 , Jan 3, 2019 |  BC Extra  |  Company News

New Year splash as BMS to acquire Celgene in $74B deal

The biggest biotech takeout in a decade brings a tumultuous 15 months for Celgene Corp. (NASDAQ:CELG) to an end as Bristol-Myers Squibb Co. (NYSE:BMY) proposed Thursday to acquire the bellwether for $74 billion. BMS cited...
17:55 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Legend reports 15 months PFS for anti-BCMA CAR; questions over trial sites linger

Data presented on the most advanced Chinese CAR product at the American Society of Hematology (ASH) meeting don't shed much light on outstanding questions related to the company's data reports from the trial, but do...
17:46 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

ASH presentations hint at future of BCMA CARs

Enhanced persistence and redirection of universal cells are among approaches companies are using to create the next generation of BCMA (tumor necrosis factor receptor superfamily member 17; TNFRSF17; CD269)-targeted CAR T cell therapies for multiple...
21:49 , Dec 4, 2018 |  BC Extra  |  Clinical News

Legend reports 15 months PFS for anti-BCMA CAR; questions over trial sites linger

Data presented on the most advanced Chinese CAR product at the American Society of Hematology (ASH) meeting on Monday don't shed much light on outstanding questions related to the company's data reports from the trial,...
00:51 , Dec 4, 2018 |  BC Extra  |  Clinical News

Weekend ASH presentations hint at future of BCMA CARs

Enhanced persistence and redirection of universal cells are among approaches companies are using to create the next generation of BCMA (tumor necrosis factor receptor superfamily member 17; TNFRSF17; CD269)-targeted CAR T cell therapies for multiple...